Zantac hit the US market as a prescription drug in 1983 before transforming into an over-the-counter heartburn treatment in 1995. GSK and Warner Lambert developed it as part of a joint venture, ...

At present, there is no proposal to prohibit the manufacture, distribution and sale of Ranitidine, a medication used to reduce stomach acid, in the country, Minister of State for Health Anupriya ...

The jury in California state court found that Zantac was dangerous and that Boehringer Ingelheim, which sold the drug from 2006 to 2017, failed to warn consumers adequately about the danger.

Illinois resident Angela Valadez had alleged that her cancer was a result of taking over-the-counter Zantac and generic versions of it from 1995 to 2014.

Zantac did not cause Brookfield woman's colon cancer, Cook County jury rules The three-week trial — a first of thousands of similar cases nationwide to appear before a jury — wrapped up Wednesday.

Zantac pharma exec calls heartburn drug safe and effective during testimony against cancer claims The executive, a medical doctor who oversaw drug safety for decades at drugmaker GSK, repeatedly ...

Zantac manufacturers still face more than 70,000 state court cases, Businessweek reports. That figure includes defendants who marketed Zantac after GSK sold the rights, plus generic manufacturers ...

The science that led to Zantac’s withdrawal is very different from the basis of the recently dismissed Zantac litigation (“The Zantac Scare and Junk Science,” Review & Outlook, Dec. 9). The ...

The drug Zantac can elevate the risk of a person developing cancer. The active ingredient, ranitidine, contains a contaminant called NDMA, which is a probable human carcinogen. The above ...

J&J lambasts Sanofi for Zantac marketing claims just as its Icy Hot pain patch campaign faces scrutiny By Ben Adams Jul 14, 2022 10:52am Sanofi drug marketing Zantac Johnson & Johnson ...

In 2019, pharmaceutical lab tests showed that Zantac and other drugs that contain ranitidine produced dangerous levels of a carcinogen known as N-Nitrosodimethylamine, commonly referred to as NDMA.

In 2019, Zantac and other ranitidine products were pulled from the shelves because research had shown that these drugs contained a probable carcinogen, which made it dangerous to consume.